RxDoctor Payments Data

Jerry Martel

Gastroenterology · Miami, FLNPI 1477755668

Payments from drug & device makers

$510,686in general payments, 2019–2025

Across 1,496 payments — averaging $341.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$173K
  • Sanofi$170K
  • Regeneron Healthcare Solutions, Inc.$76K
  • Phathom Pharmaceuticals, Inc.$38K
  • QOL Medical, LLC$34K
  • Madrigal Pharmaceuticals$3K
  • plus $15K from 33 others

What the payments were for

  • Consulting fees$17,2183%
  • Speaking & faculty fees$404,33279%
  • Travel & lodging$59,50112%
  • Food & beverage$29,3886%
  • Education$2470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510,686 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$49,962
Medicare patients
190
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase18$251,804
LinzessLinaclotide87$78,196
CreonLipase/Protease/Amylase14$61,301
RezdiffraResmetirom11$47,190
XifaxanRifaximin14$46,337
ClenpiqSod Picosulf/Mag Ox/Citric Ac222$38,437
IbsrelaTenapanor Hcl14$30,548
TrulancePlecanatide11$13,023
Dexlansoprazole DrDexlansoprazole47$12,923
Sucralfate78$11,073
DexilantDexlansoprazole14$10,017
Famotidine207$5,273
Esomeprazole Magnesium152$5,010
CholestyramineCholestyramine (With Sugar)29$4,438
Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br17$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$34,101$251,80418 claims
AbbVieLinzess, Creon$3,212$139,497101 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$173,133$59,35925 claims
Madrigal PharmaceuticalsRezdiffra$3,412$47,19011 claims
Ferring Pharmaceuticals Inc.Clenpiq$262$38,437222 claims
Ardelyx, Inc.Ibsrela$1,849$30,54814 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$781$10,01714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →